Obesity drug developer BioAge seeks up to $587 mln valuation in …
WEB2 days ago · Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Obesity drug developer BioAge seeks up to $587 million ... - Yahoo
WEB1 day ago · Obesity drug developer BioAge seeks up to $587 million valuation in US IPO. Reuters. Wed, September 18, 2024, 5:38 PM EDT · 2 min read. (Reuters) - Obesity-focused biotech BioAge Labs said on ...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEB3 days ago · (Bloomberg) -- BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public ...
BioAge Labs | Targeting metabolic aging
WEBJune 21, 2024. BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs. Explore news. We are building a pipeline of therapies to treat cardiometabolic disease by targeting the biology of human aging.
Obesity drugmaker BioAge targets $158 million in IPO
WEB2 days ago · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a ...
BioAge Announces First Patient Dosed in the STRIDES Phase 2 …
WEBJul 29, 2024 · BioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide. Trial to evaluate weight loss ...
BioAge Announces $170 Million Oversubscribed Series D …
WEBRICHMOND, Calif., February 13, 2024 -- (BUSINESS WIRE)-- BioAge Labs ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by...
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class …
WEBOct 26, 2023 · RICHMOND, Calif.-- ( BUSINESS WIRE )--BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy...
BioAge Announces Positive Topline Results for BGE-105 in Phase …
WEBDec 5, 2022 · BioAge has multiple programs targeting muscle, immune, and brain aging, including the clinical-stage apelin receptor agonist BGE-105 and a differentiated CNS-penetrant NLRP3 inhibitor.
GLP-1 excitement pushes BioAge into new age with $170M series D
WEBFeb 13, 2024 · | The frenzy around GLP-1s has changed BioAge’s trajectory, as its one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss.
- Some results have been removed
Skip to content